sponsored
PatientsVille.com Logo

PatientsVille

Gadolinium Medical Research Studies

Up-to-date List of Gadolinium Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Gadolinium Medical Research Studies

Rank Status Study
1 Recruiting Long-Term Retention of Gadolinium in Bone
Condition: Focus: Long-term Retention of Gadolinium Contrast Agent Received [Independent of Indication]
Intervention: Procedure: Gadolinium analysis in bone and tissue samples
Outcome Measures: Concentration of total Gadolinium in (trabecular/cortical) bone;   Concentration of total Gd in skin tissue samples
2 Not yet recruiting ASIS for GAMMAGARD in Primary Immunodeficiency
Condition: Primary Immunodeficiency
Interventions: Drug: Gadolinium For abdomen;   Drug: Gadolinium For lower back;   Drug: Efficacy of Gammagard subcutaneously at Week 12;   Drug: Efficacy of Gammagard subcutaneously at Week 24;   Drug: Efficacy of Gammagard subcutaneously at Week 36;   Drug: Efficacy of Gammagard subdermally at Week 36;   Drug: Efficacy of Gammagard subdermally at Week 12;   Drug: Efficacy of Gammagard subdermally at Week 24;   Drug: Adverse Reactions of Gammagard subcutaneously at Week 12;   Drug: Adverse Reactions of Gammagard subcutaneously at Week 24;   Drug: Adverse Reactions of Gammagard subcutaneously at Week 36;   Drug: Adverse Reactions of Gammagard subdermally at Week 12;   Drug: Adverse Reactions of Gammagard subdermally at Week 24;   Drug: Adverse Reactions of Gammagard subdermally at Week 36
Outcome Measures: Relative Prolongation Ability Score for Gadolinium subdermally injected;   Efficacy of GAMMAGARD subcutaneously vs. subdermally in Primary Immunodeficiency
3 Not yet recruiting ASIS for Enbrel in Plaque Psoriasis
Condition: Plaque Psoriasis.
Interventions: Drug: Gadolinium;   Drug: Efficacy of Enbrel subcutaneously at Week 12;   Drug: Efficacy of Enbrel subcutaneously at Week 24;   Drug: Efficacy of Enbrel subcutaneously at Week 36;   Drug: Efficacy of Enbrel subdermally at Week 12;   Drug: Efficacy of Enbrel subdermally at Week 24;   Drug: Efficacy of Enbrel subdermally at Week 36;   Drug: PASI 75 n(%) subcutaneously at Week 12;   Drug: PASI 75 n(%) subcutaneously at Week 24;   Drug: PASI 75 n(%) subcutaneously at Week 36;   Drug: PASI 75 n(%) subdermally at Week 12;   Drug: PASI 75 n(%) subdermally at Week 24;   Drug: PASI 75 n(%) subdermally at Week 36;   Drug: Adverse Reactions of Enbrel subcutaneously;   Drug: Adverse Reactions of Enbrel subdermally at Week 36
Outcome Measures: Relative Prolongation Ability Score for Gadolinium subdermally injected.;   Efficacy of Enbrel subcutaneously vs. subdermally in Plaque Psoriasis.
4 Not yet recruiting ASIS for Botox in Cervical Dystonia
Conditions: Cervical Dystonia Adults ,;   Abnormal Head Position and Neck Pain for These 7 Muscle Groups: Splenius,Scalene,Sterno-cleido-mastoid,Levator Scapulae,Semispinalis,Trapezius,and Longissimus.
Interventions: Drug: Gadolinium;   Drug: Efficacy of Botox intramuscularly at Week 6;   Drug: Efficacy of Botox intramuscularly at Week 12;   Drug: Efficacy of Botox intramuscularly at Week 18;   Drug: Efficacy of Botox intramuscularly at Week 24;   Drug: Efficacy of Botox intramuscularly at Week 30;   Drug: Efficacy of Botox subdermally at Week 6;   Drug: Efficacy of Botox subdermally at Week 12;   Drug: Efficacy of Botox subdermally at Week 18;   Drug: Efficacy of Botox subdermally at Week 24;   Drug: Efficacy of Botox subdermally at Week 30;   Drug: Adverse Reactions of Botox intramuscularly;   Drug: Adverse Reactions of Botox subdermally
Outcome Measures: Relative Prolongation Ability Score for Gadolinium subdermally injected.;   Efficacy of Botox intramuscularly vs. subdermally in Cervical Dystonia.
5 Not yet recruiting ASIS for Botox in Upper Limb Spasticity
Conditions: Upper Limb Spasticity Unilaterally in Adults With History of Stroke;   Increased Muscle Tone in Elbow, Wrist, Finger, and Thumb Flexors.
Interventions: Drug: Gadolinium;   Drug: Efficacy of Botox intramuscularly at Week 6;   Drug: Efficacy of Botox intramuscularly at Week 12,;   Drug: Efficacy of Botox intramuscularly at Week 18;   Drug: Efficacy of Botox intramuscularly at Week 24;   Drug: Efficacy of Botox intramuscularly at Week 30;   Drug: Efficacy of Botox subdermally at Week 6;   Drug: Efficacy of Botox subdermally at Week 12;   Drug: Efficacy of Botox subdermally at Week 18;   Drug: Efficacy of Botox subdermally at Week 24;   Drug: Efficacy of Botox subdermally at Week 30;   Drug: Adverse Reactions of Botox intramuscularly;   Drug: Adverse Reactions of Botox subdermally
Outcome Measures: Relative Prolongation Ability Score for Gadolinium subdermally injected.;   Efficacy of Botox intramuscularly vs. subdermally in Upper Limb Spasticity.
6 Not yet recruiting ASIS for Botox in Chronic Migraine
Condition: Chronic Migraine More than15 Days Per Month, and Lasting 4 Hours a Day or Longer.
Interventions: Drug: Gadolinium;   Drug: Efficacy of Botox intramuscularly at Week 6;   Drug: Efficacy of Botox intramuscularly at Week 12;   Drug: Efficacy of Botox intramuscularly at Week 18;   Drug: Efficacy of Botox intramuscularly at Week 24,;   Drug: Efficacy of Botox intramuscularly at Week 30;   Drug: Efficacy of Botox subdermally at Week 6;   Drug: Efficacy of Botox subdermally at Week 12;   Drug: Efficacy of Botox subdermally at Week 18;   Drug: Efficacy of Botox subdermally at Week 24;   Drug: Efficacy of Botox subdermally at Week 30;   Drug: Adverse Reactions of Botox intramuscularly;   Drug: Adverse Reactions of Botox subdermally
Outcome Measures: Relative Prolongation Ability Score for Gadolinium subdermally injected.;   Efficacy of Botox intramuscularly vs. subdermally in Chronic Migraine.
7 Recruiting Studying Repeated DCE-MRI and DWI in Patients Diagnosed With Prostate Cancer
Condition: Prostate Cancer
Intervention: Other: motexafin Gadolinium
Outcome Measures: Repeatability assessment of DCE-MRI metrics Ktrans and blood-normalized initial area under the Gadolinium curve (IAUGC90bn) and the DWI metric D(t);   Test-retest performance, assessed by the RC of Ktrans, IAUGC90bn, and D(t), and measured by median pixel values of the prostate tumor;   Reader effect on the RC of DCE-MRI and DWI metrics for whole prostate and tumor nodule target lesion;   Comparison between T1-dependent or T1-independent methods for Gadolinium quantification produce differing values for the RC for Ktrans
8 Recruiting Ferumoxytol and Gadolinium Magnetic Resonance Imaging (MRI) at 3 Tesla (T) and 7 Tesla (T) in Patients With Malignant Brain Tumors
Condition: Brain Neoplasms
Intervention: Drug: Ferumoxytol
Outcome Measures: The primary objective of this project is to compare quantitative imaging measures of brain tumor vascularity obtained from 3 Tesla (T) and 7 Tesla (T) MRI instruments;   To compare blood brain barrier permeabilities of Ferumoxytol and a standard Gadolinium based MRI contrast agent.;   To compare cerebral blood volume (CBV) measurements obtained using a standard Gadolinium MRI contrast agent and ferumoxytol CBV will be quantified using dynamic susceptibility contrast (DSC) techniques using both Gd and Ferumoxytol contrast agents.;   To compare perfusion and permeability parameters between treated and untreated patients;   To determine the microscopic distribution of ferumoxytol particles in tissue removed from patients undergoing surgery. .
9 Recruiting Imaging Vascular Properties of Pediatric Brain Tumors Using Ferumoxytol and Gadolinium in a Single Imaging Session
Condition: Brain Neoplasms
Intervention: Drug: ferumoxytol
Outcome Measures: Describe pediatric brain tumor vascular properties using ferumoxytol for DSC-MRI and Gadolinium-based contrast agent (GBCA) for DCE-MRI in a single MRI session.;   Describe evolving tumor vasculature imaging characteristics using DSC-MRI with ferumoxytol and DCE-MRI with GBCA.;   Compare and evaluate magnetic resonance angiogram (MRA) with ferumoxytol between different time points.;   Describe number and size of tumors imaged;   Assess histology and electron microscope (EM) on tissue samples;   Demonstrate differences in patients with prior therapy vs. no prior therapy (radiation and/or chemotherapy).
10 Recruiting High-Field MRI Iron-Based Contrast-Enhanced Characterization of Multiple Sclerosis and Demyelinating Diseases
Condition: Multiple Sclerosis
Interventions: Drug: Feraheme;   Drug: Gadolinium-based contrast
Outcome Measures: Number and location of enhancing brain lesions seen on 7 tesla MRI following Feraheme administration.;   Number and location of enhancing brain lesions seen on 7 tesla MRI following Gadolinium-based contrast administration.
11 Recruiting Assessing Dynamic Magnetic Resonance (MR) Imaging in Patients With Recurrent High Grade Glioma Receiving Chemotherapy
Condition: Brain Neoplasms
Intervention: Drug: Ferumoxytol
Outcome Measures: The primary objective of this project is to describe quantitative imaging changes of brain tumor vascularity after anti-angiogenic therapy versus steroid therapy. This objective will be accomplished with the following aims and associated hypotheses.;   To describe changes of quantitative blood brain barrier permeability measurements (Ktrans) of a standard Gadolinium (Gd) MRI contrast between bevacizumab anti-angiogenic therapy and dexamethasone.;   To describe relative cerebral blood volume (rCBV) changes obtained using ferumoxytol an iron oxide nanoparticle blood pool agent.;   To assess vascular dynamic parameters (rCBV and Ktrans) values at progression.;   To describe the changes of the vascular dynamic parameters (rCBV, Ktrans) with the changes of standard Gadolinium enhancing tumor volume;   To describe post contrast tumor volume (enhancement) of Gadolinium and ferumoxytol.
12 Recruiting 24hr Imaging Of HCC After EOVIST
Condition: Hepatocellular Carcinoma
Intervention: Drug: Eovist
Outcome Measure: Calculate the percent absolute enhancement of HCCs following Eovist administration at multiple phases
13 Recruiting An Efficacy and Safety Study of BG00012 (Dimethyl Fumarate) in Asian Subjects With Relapsing Remitting Multiple Sclerosis (RRMS)
Conditions: Relapsing-Remitting Multiple Sclerosis;   Multiple Sclerosis
Interventions: Drug: Placebo;   Drug: BG00012 (dimethyl fumarate)
Outcome Measures: Total number of new Gadolinium-enhancing lesions over 4 scans at Weeks 12, 16, 20, and 24.;   Incidence of treatment-emergent adverse events and serious adverse events;   Cumulative number of new Gadolinium-enhancing lesions from Baseline to Week 24;   Number of new or newly enlarging T2 hyperintense lesions at Week 24 compared with Baseline
14 Recruiting Identification of Adverse Plaque Characteristics by Coronary MR Angiography
Condition: Coronary Artery Disease
Intervention: Other: Coronary MR Angiography (CMRA)
Outcome Measure: Adverse plaque characteristics present on CMRA
15 Recruiting A Multicenter Trial of AS902330 (Recombinant Human Fibroblast Growth Factor-18) or Placebo After Microfracture Surgery for Cartilage Injury of the Knee
Conditions: Cartilage Repair of Knee;   Microfracture Surgery of Knee
Interventions: Drug: AS902330 (30 microgram [mcg] );   Drug: AS902330 (100 microgram [mcg]);   Drug: Placebo
Outcome Measures: Composition of the refilled cartilage measured by delayed Gadolinium-enhanced Magnetic Resonance Imaging (MRI) of cartilage (dGEMRIC) T1 relaxation time at Month 6 post-MFx surgery;   Composition of the refilled cartilage measured by delayed Gadolinium-enhanced Magnetic Resonance Imaging (MRI) of cartilage (dGEMRIC) T1 relaxation time;   Change from Baseline in patient reported outcome measure: Knee Injury and Osteoarthritis Outcome Score (KOOS) sub-scores for pain and activities of daily living (ADL);   Change from Baseline in patient reported outcome measure: Total KOOS score, KOOS sub-scores dimensions and Total KOOS minus Function in Sports and Recreational Activities (FSR) sub score;   Change from Baseline in patient reported outcome measure: Numeric Rating Scale (NRS);   Change from Baseline in patient reported outcome measure: Lower Extremity Activity Scale (LEAS);   Change from Baseline in the physician-reported outcome measure: Lysholm Knee Scale score;   Composition of the refilled cartilage as evaluated through T2 mapping;   Volume of the refilled cartilage;   Magnetic Resonance Observation of Cartilage Repair Tissue (MOCART) scores;   Six-minute walk test
16 Recruiting 3T MRI Biomarkers of Glioma Treatment Response
Conditions: Adult Anaplastic Astrocytoma;   Adult Anaplastic Ependymoma;   Adult Anaplastic Oligodendroglioma;   Adult Giant Cell Glioblastoma;   Adult Glioblastoma;   Adult Gliosarcoma;   Recurrent Adult Brain Tumor
Interventions: Device: 3-Tesla magnetic resonance imaging;   Device: CEST-MRI;   Device: DW-MRI;   Device: DCE-MRI;   Device: DSC-MRI;   Drug: IV administration of Gadolinium-containing contrast agent
Outcome Measures: Best Response;   Progression Free Survival (PFS)
17 Recruiting Artifact-Free High-Resolution Myocardial Perfusion MRI in Subjects With Abnormal Nuclear Myocardial Perfusion Studies
Conditions: Coronary Artery Disease;   CAD
Interventions: Drug: regadenoson;   Drug: Optimark®;   Device: Myocardial perfusion MRI
Outcome Measure: Presence and severity of perfusion deficit on images
18 Recruiting Contrast- Enhanced Whole-Heart Coronary MRA at 3.0T (Tesla)
Condition: Coronary Artery Disease
Interventions: Other: Image Quality;   Other: Diagnostic Accuracy
Outcome Measure: Diagnostic performance of 3.0-T contrast-enhanced whole-heart coronary MRA in patients with suspected coronary artery disease (CAD)
19 Unknown  Comparative Evaluation of Various Combinable Magnetic Resonance (CMR) Pulse-sequences for Macrophage Imaging Using Ferucarbotran
Condition: Acute Myocardial Infarction
Intervention: Drug: Ferucarbotran (Resovist)
Outcome Measure: Extent of myocardial infarction (as demonstrated with Gadolinium-based necrosis/ fibrosis imaging compared to macrophage imaging using ferucarbotran)
20 Recruiting Raltegravir (Isentress) Pilot Study in Relapsing Multiple Sclerosis
Condition: Relapsing Remitting Multiple Sclerosis
Intervention: Drug: Raltegravir
Outcome Measures: The number of new or recurrent Gd-enhancing lesions that appear on brain T1-weighted MRI;   The cumulative number of new or enlarging T2 weighted lesions on brain MRI;   Change in score on Multiple Sclerosis Functional Composite (MSFC);   Changes in Kurtzke Extended Disability Status Scale (EDSS) score;   Cumulative number of Gd-T1 enhancing lesions;   Percent of subjects with scans free from enhancing lesions in Raltegravir treated subjects vs. baseline

These studies may lead to new treatments and are adding insight into Gadolinium etiology and treatment.

A major focus of Gadolinium research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.


Discuss Gadolinium